WO2002004645A2 - A second human heparanase, and splice variants thereof, with a predominant expression in skeletal muscle, heart and pancreas - Google Patents
A second human heparanase, and splice variants thereof, with a predominant expression in skeletal muscle, heart and pancreas Download PDFInfo
- Publication number
- WO2002004645A2 WO2002004645A2 PCT/EP2001/008094 EP0108094W WO0204645A2 WO 2002004645 A2 WO2002004645 A2 WO 2002004645A2 EP 0108094 W EP0108094 W EP 0108094W WO 0204645 A2 WO0204645 A2 WO 0204645A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heparanase
- hep2
- polypeptide
- seq
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01166—Heparanase (3.2.1.166)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
Definitions
- the present invention relates to the field of carbohydrates and more specifically to the field of heparan sulphate proteoglycans.
- a novel polynucleotide has been identified encoding heparanase activity. This is the second gene encoding heparanase catalytic activity which is identified in humans.
- Several splice variants of said gene have been identified with a specific expression pattern in skeletal muscle, heart and pancreas.
- Heparan sulfate proteoglycans are ubiquitous macromolecules associated with the cell surface and extracellular matrix (ECM) of a wide range of cells of vertebrate and invertebrate tissues (David G., (1993), Faseb J. 7, 1023).
- the basic HSPG structure consists of a protein core to which several linear heparan sulfate (HS) chains are covalently attached.
- the HS chains are typically composed of repeating hexuronic acid and D-glucosamine disaccharide units that are substituted to a varying extent with N-and O-linked sulfate moieties and N-linked acetyl groups (Kjellen L.
- HSPGs heparan sulphate proteoglycans
- HS chain structures Various ligands and their receptors can show selectivity in their binding affinities to distinct HS chain structures (Lyon M. & Gallagher J.T., (1998), Matrix Biol. 17, 485). These chains can be attached to one or more specific core proteins, each with a distinctive tissue-specific expression pattern and cellular localization. Also, HSPGs can be selectively shed from the cell surface to yield soluble effectors.
- HSPGs are prominent components of blood vessels (Wight T.N., (1989), Arteriosclerosis 9, 1). In capillaries they are found mainly in the subendothelial basement membrane, where they support the vascular endothelium and stabilize the structure of the capillary wall. Cleavage of HS therefore plays a decisive part in the extravasation of blood-borne cells. In fact, expression of HS-degrading endoglycosidases, commonly called 'heparanases', correlates with the metastatic potential of mouse lymphoma, fibrosarcoma and melanoma cell lines (Vlodavsky I. et al. (1983), Cancer Res. 43, 2704).
- heparanase inhibitors for example, non-anticoagulant species of low-molecular-weight heparin and polysulfated saccharides
- Treatment of experimental animals with heparanase inhibitors considerably reduced the incidence of lung metastases by melanoma, Lewis lung carcinoma and mammary adenocarcinoma cells (Vlodavsky I., et al., (1995), Invasion Metastasis 14, 290).
- Heparanase-inhibiting molecules also inhibit T cell-mediated delayed-type hypersensitivity and experimental autoimmune encephalomyelitis and adjuvant arthritis (Vlodavsky I., et al., (1992), Invasion Metastasis 12, 112), reflecting a role in cell diapedesis and extravasation associated with inflammation and autoimmunity.
- Endoglycosidases mainly endo-beta- D-glucuronidases, capable of partially depolymerising HS chains, have been demonstrated in a variety of cells and tissues.
- heparanases are implicated in angiogenesis, tissue repair, inflammation, diabetes, asthma and lipid metabolism by releasing HS-bound growth factors and enzymes such as for example basic fibroblast growth factor (bFGF) and lipoprotein lipase.
- bFGF basic fibroblast growth factor
- bFGF basic fibroblast growth factor
- heparanase-1 or hepl The cDNA sequences of the first mammalian heparanase (heparanase-1 or hepl) from human placenta and platelets have recently been reported (Vlodavsky I. et al., (1999), Nat. Med. 5, 793; Hulett et al., (1999), Nat. Med. 5, 803; Kussie et al., (1999), Biochem. Biophys. Res. Commun. 261 , 183), US 5968822 and PCT/EP99/00777). Since it is generally accepted that all cell types express one or multiple or even specific heparanases it is possible that many more structurally distinct genes exist that encode other heparanases.
- the novel heparanase cDNA has a specific expression level that is mainly restricted to the heart, pancreas and skeletal muscle. Furthermore, contrary to what is reported in WO 01/21814, we have shown that the isolated hep2 is catalytically active.
- Fig. 1 Splice variants of heparanase 2.
- CaCo2-cells The four different splice variants as drawn in Fig.1 were identified via RACE experiments and verified by PCR using primer pairs flanking the splice variant site AB.
- Table 4 Expression patterns of heparanase 1 and heparanase 2 Multiple tissue northerns (clontech) were probed with the C-terminal portion of heparanase 2 amplified with primers PR22-10/PR22-11.
- Hep2 is also expressed in the human colon carcinoma cell line CaCo2 as shown by RT-PCR. Aims of the invention
- the current invention aims at providing a polynucleotide and functional fragments thereof, designated as Hep2, encoding a polypeptide having heparanase catalytic activity, vectors including the same, transduced cells expressing Hep2 and a recombinant polypeptide or functional fragment thereof having heparanase 2 activity.
- the invention aims at providing specific splice variants of Hep2.
- the invention further aims at providing a screening method for molecules that have a potential at antagonizing or agonizing the heparanase 2 catalytic activity.
- the invention also aims at providing molecules obtained from the screening assay that can be used for the manufacture of a medicament.
- Another aim of the invention is to provide an antibody that specifically recognizes and binds to a Hep2 polypeptide.
- the invention aims at using polymorphisms of the Hep2 sequence to identify individuals having a predisposition to acquire diseases resulting from a shortage or excessive activity of heparanase 2 activity.
- a polynucleotide referred to hereinbelow as Hep2, Hep2 cDNA or Hep2 gene encoding a polypeptide having heparanase catalytic activity, vectors including the same, transduced host cells expressing said heparanase and a recombinant protein having said heparanase catalytic activity.
- polynucleotide may be interpreted to mean the DNA and cDNA sequence as detailed by Yoshikai et al. (1990) Gene 87:257, with or without a promoter DNA sequence as described by Salbaum et al. (1988) EMBO J. 7(9):2807.
- fragment refers to a polypeptide or polynucleotide of at least about 9 amino acids or 27 base pairs, typically 50 to 75, or more amino acids or base pairs, wherein the polypeptide contains an amino acid core sequence.
- a fragment may be for example a truncated Hep2 isoform, modified Hep2 isoform (as by amino acid substitutions, deletions, or additions outside of the core sequence), or other variant polypeptide sequence, but is not a naturally-occurring Hep2 isoform that is present in a human individual. If desired, the fragment may be fused at either terminus to additional amino acids or base pairs, which may number from 1 to 20, typically 50 to 100, but up to 250 to 500 or more.
- a "functional fragment” means a polypeptide fragment possessing the biological property of having heparanase catalytic activity or a polynucleotide fragment encoding heparanase catalytic activity.
- SEQ ID NO: 2 is the correct amino acid sequence of hep2 and that amino terminal extensions of SEQ ID NO: 2 lead to catalytically inactive hep2: (1) in silico analysis of SEQ ID NO: 1 shows that the sequence context upstream of the first ATG- initiation codon figures a pyrimidine (T) at the minus-3 position, which makes it a far less than optimal Kozak sequence.
- T pyrimidine
- the second ATG-initiation codon in contrast, is preceded by a GCC codon, figuring a purine (G) at the minus-3 position and also perfectly matching the Kozak consensus sequence (G/ACCATG) at the minus-2 and minus-1 positions, (2) translation of the protein from the first ATG codon on would result in a protein that lacks a typical signal sequence.
- polynucleotide sequence which includes polynucleotide fragments encoding polypeptides having heparanase catalytic activity.
- polynucleotide fragment includes nucleotides 85-1833 of SEQ ID NO: 1 , which encodes the entire human heparanase 2 enzyme (Hep2).
- Hep2 cDNAs (splice variants), generated as a result of alternative splicing, encoding human Hep 2AB (set forth in SEQ ID NO: 2), Hep 2A (set forth in SEQ ID NO: 4), Hep 2B (set forth in SEQ ID NO: 6) and Hep 2- - (set forth in SEQ ID NO: 8) were isolated containing 582, 524, 528 and 470 amino acid residues, respectively.
- the polynucleotide sequence which encodes the polypeptide having heparanase 2 activity shares at least 60% homology, preferably at least 70% homology more preferably at least 80% homology, most preferably at least 90% homology with SEQ ID NO:1. Homology is determined using default parameters of a DNA sequence analysis software package developed by the Genetic Computer Group (GCG) at the University of Wisconsin.
- GCG Genetic Computer Group
- the polynucleotide fragment according to the present invention includes a portion (fragment) of SEQ ID NO:1 which encodes a polypeptide having the heparanase catalytic activity.
- the polypeptide encoded by the polynucleotide fragment includes an amino acid sequence as set forth in SEQ ID NO:2 or a functional fragment thereof.
- polynucleotide sequence encodes a polypeptide having heparanase activity, which shares at least 60% homology, preferably at least 70% homology, more preferably at least 80% homology, most preferably at least 90% homology with SEQ ID NO: 2.
- the polynucleotide fragment encodes a polypeptide having heparanase activity, which may therefore be allelic, species and/or induced variant of the amino acid sequence set forth in SEQ ID NO:2. It is understood that any such variant may also be considered a homolog.
- allelic variant is used herein to denote any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence.
- allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.
- a single stranded polynucleotide fragment which includes a polynucleotide sequence complementary to at least a portion of a polynucleotide strand encoding a polypeptide having heparanase 2 catalytic activity as described above.
- the expression pattern of Hep2 mRNA in various tissues and cell lines was investigated using RT-PCR. Hep2 was found to be expressed in tissues and cells previously known to have heparanase activity. However, the observed expression pattern is completely different from the previously identified heparanase (Hulett et al, (1999), Nat. Med. 5, 803).
- Hep2 which is mainly observed in skeletal muscle, pancreas and heart and to a lesser extent in kidney and lung
- Hep2, or a specific splice variant thereof can be a target for the treatment of asthmatic patients.
- an enhanced proteoglycan deposition and/or turnover contributes to the airway wall remodelling observed in asthmatics (Huang et al. (1999) Am J Respir Crit Care Med, 160, 725 and Roberts and Burke (1998) Can Respir J 5, 48).
- Hep2, or a specific splice variant thereof can be a target for the treatment of human pancreatic cancer.
- the heparan sulfate proteoglycan, glypican-1 is strongly overexpressed in human pancreatic cancer (Kleeff et al. (1998) J Clin Invest, 102, 1662) and hence it is proposed that glypican-1 plays an essential role in the responses of pancreatic cancer cells to certain mitogenic stimuli. Consequently, use of a medical preparation comprising an agonist of Hep2, or a specific splice variant thereof, could be useful for the treatment of pancreatic cancer.
- skeletal muscle fibers are surrounded by an extracellular matrix which is composed of glycoproteins, collagen, and proteoglycans. It has been observed that an upregulation of proteoglycans is positively correlated with skeletal muscle regeneration (Caceres et al. (2000) Eur J Cell Biol 79, 173). Also here it can be envisaged that the inhibition of Hep2, or a specific splice variant thereof, can be useful for the treatment of dystrophic muscular diseases.
- proteoglycans are abnormally high around degenerated elastic fibres and collagen fibres (Akhtar el al. (1999) Cardiovasc Pathol 4, 191). Also in experimental induced myocardial infarction models an increase of specific proteoglycans is observed (Doi et al ((2000) Pathol Res Pract 196, 23). It can be expected that a medical preparation comprising an agonist of Hep2 can be useful for the prophylaxis and/or treatment of heart diseases.
- Circulating tumor cells arrested in the capillary beds of different organs must invade the endothelial cell lining and degrade its underlying basement membrane (BM) in order to invade into the extravascular tissue(s) where they establish metastasis (Nicolson G.L., (1988), Cancer Met. Rev. 7, 143).
- BM basement membrane
- the invading cells must degrade the subendothelial glycoproteins and proteoglycans of the BM in order to migrate out of the vascular compartment.
- HS degrading heparanase was found to correlate with the metastatic potential of mouse lymphoma (Vlodavsky I.
- Fibroblast growth factors are a family of structurally related polypeptides characterized by high affinity to heparin (Burgess W.H. & Maciag T., (1989), Annu. Rev. Biochem. 58, 575). They are highly mitogenic for vascular endothelial cells and are among the most potent inducers of neovascularization (Burgess W.H. & Maciag T., (1989), Annu. Rev. Biochein. 58, 575).
- bFGF Basic fibroblast growth factor
- bFGF binds to HSPG in the ECM and can be released in an active form by HS degrading enzymes (Ishai-Michaeli R. et al, (1992), Biochemistry 31 , 2080). It was demonstrated that heparanase activity expressed by platelets, mast cells, neutrophils and lymphoma cells is involved in release of active bFGF from ECM and basement membranes (Ishai-Michaeli R. et al, (1990), Cell Reg.
- heparin and HS are involved in binding of bFGF to high affinity cell surface receptors and in bFGF cell signaling (Spivak-Kroizman T. et al, (1994), Cell 79, 1015). Moreover, the size of HS required for optimal effect was similar to that of HS fragments released by heparanase (Ornitz D. et al (1995), Science 268, 432). Similar results were obtained with vascular endothelial cells growth factor (VEGF) (Gitay-Goren H. et al, (1992), J. Biol. Chem. 267, 6093), suggesting the operation of a dual receptor mechanism involving HS in cell interaction with heparin-binding growth factors.
- VEGF vascular endothelial cells growth factor
- Heparanase activity correlates with the ability of activated cells of the immune system to leave the circulation and elicit both inflammatory and autoimmune responses. Interaction of platelets, granulocytes, T and B lymphocytes, macrophages and mast cells with the subendothelial ECM is associated with degradation of HS by a specific heparanase activity (Vlodavsky I. et al., (1992), Invasion & Metastasis 12, 112).
- the enzyme is released from intracellular compartments (e.g., lysosomes, specific granules, etc.) in response to various activation signals (e.g., thrombin, calcium ionophore, immune complexes, antigens, mitogens. etc.). suggesting its regulated involvement in inflammation and cellular immunity.
- activation signals e.g., thrombin, calcium ionophore, immune complexes, antigens, mitogens. etc.
- mammalian heparanase may be applied to modulate: bioavailability of heparin-binding growth factors (Ruoslahti E. and Yamaguchi Y., (1991), Cell 64, 867); cellular responses to heparin-binding growth factors (e.g., bFGF, VEGF) and cytokines (IL-8) (Gitay-Goren H. et al, (1992), J. Biol. Chem. 267, 6093); cell interaction with plasma lipoproteins (Eisenberg S. et al, (1992), J. Clin. Invest.
- heparin-binding growth factors e.g., bFGF, VEGF
- IL-8 cytokines
- Heparanase-2 or a specific splice variant thereof, may thus prove useful for conditions such as wound healing, angiogenesis, restenosis, atherosclerosis, inflammation, neurodegenerative diseases and viral infections.
- Mammalian heparanase-2, or a specific splice variant thereof, can be used to neutralize plasma heparin as a potential replacement of protamine.
- Anti- heparanase-2 or a specific splice variant thereof, antibodies may be applied for immunodetection and diagnosis of micrometastases, autoimmune lesions and renal failure in biopsy specimens, plasma samples, and body fluids. Common use in basic research is expected. The presence of heparan sulphate on cell surfaces has been shown to be the principal requirement for the binding of Herpes Simplex (Shieh M.T. et al, (1992), J. Cell Biol. 116, 1273) and Dengue (Chen Y. et al, (1997), Nature Medicine 3, 866) viruses to cells and for subsequent infection of the cells.
- heparanase-2 Removal of the cell surface heparan sulfate by heparanase-2, or a specific splice variant thereof, may therefore abolish virus infection.
- treatment of cells with bacterial heparitinase (degrading heparan sulphate) or heparinase (degrading heparin/heparan sulphate) reduced the binding of two related animal herpes viruses to cells and rendered the cells at least partially resistant to virus infection (Shieh M.T. et al, (1992), J. Cell Biol. 116, 1273).
- the cell surface heparan sulphate is also involved in HIV infection (Putnak J.R. et al, (1997) Nature Medicine 3, 828).
- Heparan sulfate proteoglycans were identified in the prion protein amyloid plaques of Gerstmann-Straussler Syndrome, Creutzfeldt-Jakob disease and Scrapie (Narindrasorasak S. et al, (1991), J. Biol. Chem. 266, 12878). Heparanase-2, or a specific splice variant thereof, may disintegrate these amyloid plaques which are also thought to play a role in the pathogenesis of Alzheimer's disease.
- SMCs arterial smooth muscle cells
- HS heparin-binding growth factors
- a vector including a polynucleotide sequence encoding a polypeptide having heparanase-2 catalytic activity.
- the vector may be of any suitable type including, but not limited to, a phage, virus, plasmid, phagemid, cosmid, bacmid or even an artificial chromosome.
- the polynucleotide sequence encoding a polypeptide having heparanase 2 catalytic activity may include any of the above described polynucleotide fragments.
- the term "regulatory element” refers to a genetic element which controls some aspect of the expression of nucleic acid sequences.
- a promoter is a regulatory element that facilitates the initiation of transcription of an operably linked coding region.
- Other regulatory elements are splicing signals, polyadenylation signals, termination signals, etc.
- Transcriptional control signals in eucaryotes comprise "promoter” and "enhancer” elements. Promoters and enhancers consist of short arrays of DNA sequences that interact specifically with cellular proteins involved in transcription [Maniatis, T. et al., Science 236:1237 (1987)]. Promoter and enhancer elements have been isolated from a variety of eukaryotic sources including genes in yeast, insect and mammalian cells and viruses (analogous control elements, i.e., promoters, are also found in procaryotes).
- telomere binding site The selection of a particular promoter and enhancer depends on what cell type is to be used to express the protein of interest. Some eukaryotic promoters and enhancers have a broad host range while others are functional in a limited subset of cell types [for review see Voss, S. D. et al., Trends Biochem. Sci., 11:287 (1986) and Maniatis, T. et al., supra (1987)].
- the term "recombinant DNA vector” as used herein refers to DNA sequences containing a desired coding sequence and appropriate DNA sequences necessary for the expression of the operably linked coding sequence in a particular host organism (e.g. mammal). DNA sequences necessary for expression in procaryotes include a promoter, optionally an operator sequence, a ribosome binding site and possibly other sequences. Eukaryotic cells are known to utilize promoters, polyadenlyation signals and enhancers.
- a host cell that includes an exogenous polynucleotide fragment including a polynucleotide sequence encoding a polypeptide having heparanase 2 catalytic activity.
- the exogenous polynucleotide fragment may be any of the above described fragments.
- the host cell may be of any type such as prokaryotic cell, eukaryotic cell, a cell line, or a cell as a portion of a multicellular organism (e.g., cells of a transgenic organism).
- a recombinant protein including a polypeptide having heparanase 2 catalytic activity.
- the recombinant protein may be purified by any conventional protein purification procedure close to homogeneity and/or be mixed with additives.
- the recombinant protein may be manufactured using recombinant expression systems comprising bacterial cells, yeast cells, animal cells, insect cells, plant cells or transgenic animals or plants.
- a pharmaceutical composition comprising as an active ingredient a recombinant protein having heparanase 2 catalytic activity.
- a medical equipment comprising a medical device containing, as an active ingredient a recombinant protein having heparanase 2 catalytic activity.
- a heparanase overexpression system comprising a cell overexpressing heparanase 2 catalytic activity.
- the cell may be a host cell transiently or stably transfected or transformed with any suitable vector which includes a polynucleotide sequence encoding a polypeptide having heparanase activity and a suitable promoter and enhancer sequences to direct expression of heparanase 2.
- the overexpressing cell may also be a product of an insertion (e.g.
- 'overexpression refers to a level of expression which is higher than a basal level of expression typically characterizing a given cell under otherwise identical conditions.
- the present invention can be used to develop assays to identify molecules to inhibit for example tumor cell metastasis, inflammation and autoimmunity.
- the identification of the Hep2 gene encoding for heparanase 2 enzyme enables the production of a recombinant enzyme in heterologous expression systems, alternatively the Hep 2 can be purified from cell lines expressing naturally Hep 2 by methods known in the art.
- Heparanase inhibitors mainly based on heparin and similar polysaccharides, in the prior art have been shown to inhibit tumour growth and/or metastasis, angiogenesis and vascular damage in some cases in experimental models.
- the availability of large quantities of recombinant enzyme and sensitive functional assays will facilitate the design and testing of better and more selective inhibitors.
- balance is essential, and the finding that for example bFGF signalling is facilitated when bound to cell surface HS cautions that use of heparanase inhibitors may shift the balance from free bFGF to HS-bFGF, alter recycling and degradation pathways and enhance rather than inhibit cellular activation. Careful evaluation of possible adverse effects on normal physiological functions will also be imperative.
- agonists can be identified with the screening assay and can be used to manufacture a medicament, or in gene therapy, for treatment of diseases where a shortage of Hep 2 occurs. Therefore the invention also provides methods for identifying compounds or molecules which bind on the Hep2 polypeptide or a functional fragment thereof and interfere with its catalytic heparanase2 activity. These methods are also referred to as 'drug screening assays' or 'bioassays' and typically include the step of screening a candidate/test compound or agent for the ability to interact with Hep2.
- Candidate compounds or agents, which have this ability can be used as drugs to combat or prevent for example tumour invasion.
- Small molecules e.g. small organic molecules, and other drug candidates can be obtained, for example, from combinatorial and natural product libraries.
- Random peptide libraries consisting of all possible combinations of amino acids attached to a solid phase support may also be used to identify peptides that are able to bind to specific ligands (Lam KS et al., 1991 , Nature 354, 82). Identification of molecules that are able to bind to Hep2 may be accomplished by screening a peptide library with recombinant soluble Hep2 protein.
- Assays are cell-free assays, which include the steps of combining Hep2 and a candidate/test compound, e.g., under conditions which allow for interaction of (e.g.
- the candidate/test compound binding of) the candidate/test compound with Hep2 to form a complex, and detecting the formation of a complex, in which the ability of the candidate compound to interact with Hep2 is indicated by the presence of the candidate compound in the complex.
- Formation of complexes between the Hep2 and the candidate compound can be quantitated, for example, using standard immunoassays.
- the Hep2 employed in such a test may be free in solution or affixed to a solid support.
- cell- based assays may be used to identify compounds that can interact with Hep2, an example but not limited to this, is yeast-two-hybrid and its derivatives or the specific infection by phages of cells, expressing Hep2, by phages expressing hybrid molecules that can bind to Hep2.
- Hep2 or its (their) target molecule(s) to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.
- Interaction (e.g., binding of) of Hep2 to a target molecule can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.
- a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix.
- Hep2 tagged can be adsorbed onto Ni- NTA microtiter plates, or Hep2-ProtA fusions adsorbed to IgG, which are then combined with the cell lysates (e.g., 35 S-Iabeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the plates are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated.
- the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of Hep2 binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques.
- Other techniques for immobilizing protein on matrices can also be used in the drug screening assays of the invention.
- either Hep2 or its target molecules can be immobilized utilizing conjugation of biotin and streptavidin.
- Biotinylated Hep2 can be prepared from biotin-NHS (N-hydroxy- succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, III.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).
- biotinylation kit Pierce Chemicals, Rockford, III.
- antibodies reactive to Hep2 but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and Hep2 trapped in the wells by antibody conjugation
- preparations of a Hep2-binding protein and a candidate compound are incubated in the Hep2-presenting wells of the plate, and the amount of complex trapped in the well can be quantitated.
- Methods for detecting such complexes include immunodetection of complexes using antibodies reactive to the Hep2-target molecule, or which are reactive to Hep2 and compete with the target molecule; as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.
- Another technique for drug screening which provides for high throughput screening of compounds having suitable binding affinity to Hep2 is described in detail in "Determination of Amino Acid Sequence Antigenicity" by Geysen HN, WO 84/03564, published on 13/1584.
- large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface.
- the protein test compounds are reacted with fragments of Hep2 and washed. Bound Hep2 is then detected by methods well known in the art.
- Purified Hep2 can also be coated directly onto plates for use in the aforementioned drug screening techniques.
- non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.
- This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding Hep2 specifically compete with a test compound for binding Hep2. In this manner, the antibodies can be used to detect the presence of any protein, which shares one or more antigenic determinants with Hep2.
- patent WO 00/03036 qualitative and quantitative methods of testing molecules for its potential at inhibiting heparanase in the presence of a heparanase substrate are fully described.
- the present invention also relates to molecules that can be used to neutralize the activity of Hep2 by interfering with its synthesis and/or translation.
- molecules it is meant peptides, proteins, organic molecules and carbohydrates. More specifically, the invention is directed to antagonists of Hep2 such as anti-Hep2 antibodies and functional derivatives derived thereof, anti-sense RNA and DNA molecules and ribozymes that function to inhibit the translation of Hep2.
- antagonists of Hep2 such as anti-Hep2 antibodies and functional derivatives derived thereof, anti-sense RNA and DNA molecules and ribozymes that function to inhibit the translation of Hep2.
- 'synthesis' it is meant trancription of Hep2.
- Small molecules can bind on the promoter region of Hep2 and inhibit binding of a transcription factor or said molecules can bind said transcription factor and inhibit binding to the Hep2-promoter.
- Hep2 it is meant also its isoforms, which occur as a result of alternative splicing, and allelic variants thereof.
- alternative splicing four Hep2 RNAs encoding human Hep 2AB (set forth in SEQ ID NO:2), Hep 2A (set forth in SEQ ID NO: 4), Hep 2B (set forth in SEQ ID NO: 6) and Hep 2- - (set forth in SEQ ID NO: 8) isoform precursors containing 582, 524, 528 and 470 amino acid residues, respectively, have been identified.
- the term 'antibody' or 'antibodies' relates to an antibody characterized as being specifically directed against Hep2 or any functional derivative thereof, with said antibodies being preferably monoclonal antibodies; or an antigen-binding fragment thereof, of the F(ab') 2 , F(ab) or single chain Fv type, or any type of recombinant antibody derived thereof.
- These antibodies of the invention, including specific polyclonal antisera prepared against Hep2 or any functional derivative thereof, have no cross-reactivity to others proteins.
- the monoclonal antibodies of the invention can for instance be produced by any hybridoma liable to be formed according to classical methods from splenic cells of an animal, particularly of a mouse or rat immunized against Hep2 or any functional derivative thereof, and of cells of a myeloma cell line, and to be selected by the ability of the hybridoma to produce the monoclonal antibodies recognizing Hep2 or any functional derivative thereof which have been initially used for the immunization of the animals.
- the monoclonal antibodies according to this embodiment of the invention may be humanized versions of the mouse monoclonal antibodies made by means of recombinant DNA technology, departing from the mouse and/or human genomic DNA sequences coding for H and L chains or from cDNA clones coding for H and L chains.
- the monoclonal antibodies according to this embodiment of the invention may be human monoclonal antibodies.
- Such human monoclonal antibodies are prepared, for instance, by means of human peripheral blood lymphocytes (PBL) repopulation of severe combined immune deficiency (SCID) mice as described in PCT/EP 99/03605 or by using transgenic non- human animals capable of producing human antibodies as described in US patent 5,545,806.
- PBL peripheral blood lymphocytes
- SCID severe combined immune deficiency
- fragments derived from these monoclonal antibodies such as Fab, F(ab)' 2 and scFv ("single chain variable fragment"), providing they have retained the original binding properties, form part of the present invention.
- Such fragments are commonly generated by, for instance, enzymatic digestion of the antibodies with papain, pepsin, or other proteases. It is well known to the person skilled in the art that monoclonal antibodies, or fragments thereof, can be modified for various uses.
- the antibodies involved in the invention can be labeled by an appropriate label of the enzymatic, fluorescent, or radioactive type.
- oligoribonucleotide sequences that include anti-sense RNA and DNA molecules and ribozymes that function to inhibit the translation of Hep2 mRNA.
- Anti-sense RNA and DNA molecules act to directly block the translation of mRNA by binding to targeted mRNA and preventing protein translation.
- antisense DNA oligodeoxyribonucleotides derived from the translation initiation site, e.g., between -10 and +10 regions of the Hep2 nucleotide sequence, are preferred.
- Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA.
- the mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by a endonucleolytic cleavage.
- engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of Hep2 RNA sequences.
- Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC.
- RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable.
- the suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.
- RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters.
- antisense cDNA constructs that synthesize anti-sense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.
- the above-described molecules can be used as a medicament for treatment of diseases as described herein.
- the therapeutic method of the present invention against for example, bot not limited to this, the prevention of tumour invasion can also be used in combination with any other tumour therapy known in the art such as irradiation, chemotherapy or surgery.
- the term 'medicament to treat' relates to a composition comprising molecules as described above and a pharmaceutically acceptable carrier or excipient (both terms can be used interchangeably) to treat diseases as indicated above.
- a pharmaceutically acceptable carrier or excipient both terms can be used interchangeably to treat diseases as indicated above.
- the administration of a compound, an antagonist or agonist of the Hep2 or a pharmaceutically acceptable salt thereof may be by way of oral, inhaled or parenteral administration.
- the active compound may be administered alone or preferably formulated as a pharmaceutical composition.
- a unit dose will normally contain 0.01 to 50 mg for example 0.01 to 10 mg, or 0.05 to 2 mg of Hep2 agonist or antagonist or a pharmaceutically acceptable salt thereof.
- Unit doses will normally be administered once or more than once a day, for example 2, 3, or 4 times a day, more usually 1 to 3 times a day, such that the total daily dose is normally in the range of 0.0001 to 1 mg/kg; thus a suitable total daily dose for a 70 kg adult is 0.01 to 50 mg, for example 0.01 to 10 mg or more usually 0.05 to 10 mg.
- the compound or a pharmaceutically acceptable salt thereof is administered in the form of a unit-dose composition, such as a unit dose oral, parenteral, or inhaled composition.
- compositions are prepared by admixture and are suitably adapted for oral, inhaled or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories or aerosols.
- Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
- the tablets may be coated according to well-known methods in the art.
- Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
- Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate.
- Suitable lubricants include, for example, magnesium stearate.
- Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
- solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel , or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
- Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.
- compositions for inhalation are presented for administration to the respiratory tract as a snuff or an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose.
- the particles of active compound suitably have diameters of less than 50 microns, preferably less than 10 microns, for example between 1 and 5 microns, such as between 2 and 5 microns.
- a favoured inhaled dose will be in the range of 0.05 to 2 mg, for example 0.05 to 0.5 mg, 0.1 to 1 mg or 0.5 to 2 mg.
- fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle.
- the active compound can be either suspended or dissolved.
- Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
- adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
- the composition can be frozen after filling into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active compound.
- bronchodilators for example sympathomimetic amines such as isoprenaline, isoetharine, salbutamol, phenylephrine and ephedrine; xanthine derivatives such as theophylline and aminophylline and corticosteroids such as prednisolone and adrenal stimulants such as ACTH may be included.
- sympathomimetic amines such as isoprenaline, isoetharine, salbutamol, phenylephrine and ephedrine
- xanthine derivatives such as theophylline and aminophylline
- corticosteroids such as prednisolone and adrenal stimulants such as ACTH
- compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
- the present invention further provides a pharmaceutical composition for use in the treatment and/or prophylaxis of herein described disorders which comprises a molecule or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and, if required, a pharmaceutically acceptable carrier thereof.
- Another pharmaceutically acceptable composition is an inhalation composition, suitably in unit dosage form. Such compositions may be prepared in the manner as hereinbefore described.
- a 'genetic construct' means that the coding information of Hep2, as depicted in SEQ ID No:2, or a functional fragment thereof is operably linked to elements known in the art that can provide transcription of the Hep2, such as a promoter and/or enhancer sequence.
- Gene therapy means the treatment by the delivery of therapeutic nucleic acids to patient's cells. This is extensively reviewed in Lever and Goodfellow 1995; Br. Med Bull., 51, 1-242; Culver 1995; Ledley, F.D. 1995. Hum. Gene Ther. 6, 1129. To achieve gene therapy there must be a method of delivering genes to the patient's cells and additional methods to ensure the effective production of any therapeutic genes.
- Non-viral delivery There are two general approaches to achieve gene delivery; these are non-viral delivery and virus-mediated gene delivery.
- virus-mediated gene delivery is the use of a virus-mediated gene delivery system with replication defective retroviruses to stably introduce genes into patient's cells.
- polymorphisms in the Hep2 gene can be detected and used diagnostically to identify patients at risk to develop diseases as herein described.
- Polymorphisms can occur in regulatory regions of the Hep2 gene, for example in 5' and 3' untranslated regions. Said polymorphism can induce a higher or lower expression level of Hep2.
- polymorphisms can be found in the coding region of Hep2 and can lead to less susceptibility to physiological regulation or to a lower or higher activity of Hep2.
- the invention may relate to a method of diagnosis.
- tumour tissue can be diagnosed and it can be predicted if said tumour cells have invasive and metastatic properties.
- the essential steps comprise of taking a biopsy of the tumour cells to be diagnosed, determining the original cell type, extracting total proteins of the tumour cells and measuring the amount and/or catalytic activity of heparanase2 in the presence of a suitable heparanase substrate. Said amount of Hep2 catalytic activity is compared with a reference sample, originating from normal cells of the same type, preferentially from the same individual.
- the Hep2 protein or a functional fragment thereof can be used for heparan sulphate sequencing.
- the Hep 2 protein or a functional fragment thereof can be used the preparation of low molecular weight heparin or heparan sulphate.
- heparanase homologue was identified by BLAST - searching the human EST- database, querying with the human heparanase sequence (Vlodavsky et al., (1999), Nat. Med. 5, 793).
- One EST-entry (GenBank ID: A1222323; corresponding to the partial sequence of IMAGE clone 1843155 and containing an open reading frame (ORF) of 117 nucleotides followed by a STOP codon) was identified as encoding a C- terminal peptide of 39 amino acids (aa) with moderate but possibly significant sequence similarity to the C-terminal end of heparanase (41% identities, 56% positives).
- primer pairs were designed to amplify the part of the IMAGE clone 1843155 cDNA that encoded a peptide with significant homology to heparanase (Vlodavsky et al., (1999), Nat. Med. 5, 793), corresponding to residues 1680 - 1830 of SEQ ID NO :1.
- This PCR-probe was used for the analysis of human Multiple Tissue Northern Blots (Clontech), and identified transcripts of approximately 5.4 kb in several tissues, notably in heart, skeletal muscle, pancreas, and to a lesser extent in liver, kidney and lung.
- heparanase appears to be encoded by transcripts of 4.4 and 2.0 kb (Hulett et al., 1999), this result confirmed that a distinct transcript encoding peptide related (but not identical) to heparanase was present in several polyA + -RNA preparations from different origins. Therefore, additional primers were designed for RACE experiments and the isolation of the whole coding cDNA for what is designated as heparanase 2.
- Heparanase activity-assays were performed on different transfected cell lines (293, Hela, Caco 2, MDCK, COS 1, CHO-K1), at various pH values, ranging from pH 2.5 to 7.5.
- the cells were transfected with the respective heparanase-1 (Vlodavsky I. et al., (1999) Nat. Med. 5, 793) or -2 expression-vectors, or empty vectors as controls. After 48h, the cells were lysed and the extracts were incubated with radiosulfate-labeled HS- substrates, for 18-24h.
- heparanase-2 activity was only apparent as a discrete broadening of the labelled HS band towards the lower molecular weight region. Unlike for heparanase-1, the optimal pH value for heparanase-2 activity was observed to be situated in the range of pH 5.0-6.0.
- heparanase-2 (and its splice variants herein described before) were clearly much larger than those created by heparanase-1 , indicating that heparanase-2 (and its splice variants herein described before) recognizes and cleaves sites within the HS chains that are different from and much less abundant than those that are recognized and cleaved by heparanase-1.
- HS-chains are still connected to each other via linkage (by their reducing ends) to a short protease-resistant peptide (originating from the core protein).
- a clear reduction is observed of the sizes of these HS-clusters in heparanase-2- transfected cells, which is to be expected if heparanase-2 cleaves HS within or close to the HS-protein linkage region.
- we also tagged protein- free single HS chains prepared from proteoglycan by alkaline treatment) with a fluorochrome at their reducing ends (aldehyde coupling to APTS or AMAC).
- the comparison between two different heparanase-2AB expression-constructs is currently being tested.
- the first construct (construct-1) contains both the first and the second ATG codon-sequences present in SEQ ID NO: 1.
- Translation from the first ATG can produce the hep-2 polypeptide as described in WO 01/21814, (which has an N-terminal extension of 10 amino acids (MRVLCAFPEA) as compared to SEQ ID NO: 2) or it can produce the hep-2 polypeptide claimed in the present invention (SEQ ID NO: 2).
- a second construct (construct-2) only the second ATG is retained (by changing the first ATG into GTG).
- Clones transfected with construct-1 express heparanase-2 protein and show enhanced heparanase activity (as demonstrated in our experiments, see below). However, it is expected that cells transfected with construct-2 (removal of the 1 st ATG), will express much higher levels of a hep-2 protein which can be detected by heparanase-2-specific antibody in immunoblots, and of much higher heparanase activity.
- heparanase-2AB Based on the primary protein sequence of heparanase-2AB, two potentially antigenic peptide sequences were selected which are present in all heparanase-2 splice variants, but not in heparanase-1.
- Corresponding synthetic peptides (C)+QNLRNPAKSRGGPGP (aa 116-130 of SEQ ID NO: 2) and GLQRKPRPGRVIRDK +(C) (aa 453-467 of SEQ ID NO: 2) were synthesized, with an additional cysteine (at the NH 2 - or the COOH-terminus, as indicated) to allow specific coupling to KLH (Keyhole Limpet Hemacyanin), used as carrier protein.
- KLH Keyhole Limpet Hemacyanin
- Two rabbits were immunized with the peptide mixtures, according to standard immunization protocols. Blood samples were taken, 10 days after every boost immunization. After the final bleeding, specific antibodies were isolated by affinity-purification on corresponding peptides coupled to EAH-Sepharose (wash conditions: PBS; elution conditions: 100mM Glycine pH 2.5), and stored in PBS pH 7.2, 0.01% sodium azide, 1% BSA.
- the anti-peptide antibodies react specifically with all the four splice variants of heparanase-2, in immunoblots of cells that were transfected with the different heparanase-2 splice variants, clearly revealing the size differences of the different splice variants.
- Nucleotide sequence analysis was performed using the dideoxy-mediated chain termination procedure with fluorescent primers and the Thermo Sequenase Primer Cycle Sequencing Kit (Amersham-Pharmacia). Approximately 1 ⁇ g of plasmid DNA was used as template. The reactions were performed using a Gene-amp 9600 (Perkin- Elmer) with following cycling parameters: incubation for 2.5 min at 95°C, 20 cycles of respectively 30 sec at 95°C, 30 sec at 55°C, and 1 min at 72°C. This was followed by 10 cycles of respectively 30 sec at 95°C, 1 min at 72°C. The cycle sequencing reactions were analysed by electrophoresis using an A.L.F. DNA Sequencer (Amersham- Pharmacia) on standard 30 cm, 6 % Hydrolink Long Ranger gels (AT Biochem). Sequence-analysis was performed using bio-informatic tools. Polymerase chain reaction:
- oligonucleotides were purchased from Eurogentec. PCR conditions used were identical to the ones used for RACE (see there).
- RACE was performed on a library of adaptor-ligated foetal brain cDNA, using the conditions stipulated and reagents (Marathon cDNA Amplification kit) provided by the supplier (Clontech, Palo Alto, CA).
- the cDNAs were amplified through a two-step PCR protocol.
- the first PCR used a gene-specific and an anchor primer provided by the supplier.
- 5 ⁇ l of the first PCR reaction was used as template for the second PCR- reaction, using a second gene-specific nested primer and a nested anchor primer provided by the supplier.
- the products of the second PCR were analysed by electrophoresis in a 1 % agarose gel.
- PCR-products were gel purified using either the Wizzard DNA clean-up system (Promega, Madison, Wl) or Qiaquick (Qiagen Inc., Santa Clarita, CA). PCR-products were T/A cloned using the vector pGEMTeasy. Multiple independent RACE clones were sequenced in each case. Primers AP1 (5'-CCATCCTAATACGACTCACTATAGGGC-3') and AP2 (5 ' - ACTCACTATAGGGCTCGAGCGGC-3 ' ) were contained in the Marathon ready cDNA kit of Clontech
- Premade Northern blots of poly(A) RNA from multiple human tissues were obtained from Clontech. Hybridization was performed with 32 P-oligolabeled probes for two hours at 68°C, using Expresshyb solution (Clontech) according to the manufacturer's specifications. Dehybridisation included washing at room temperature for 30 min with 2.0 % SSC, 0.05 % SDS and a high stringency wash for 30 min with 0.1 % SSC, 0.1 % SDS at 65°C.
- the extract and the medium were applied to a DEAE column (5ml packed beads). Columns were washed with 5 column volumes TUT buffer (6M Urea, 50mM Tris pH 8.0, 0.5% Triton X-100) containing 200mM NaCl, followed by 2 column volumes of TUT-buffer, and eluted by 2 column volumes 1M NaCl in TUT buffer. The eluant was adjusted to 200mM NaCl with TUT-buffer and reconcentrated on a DEAE-column (250 ⁇ l packed beads) equilibrated with 200mM NaCl, 20mM Tris pH 7.4, 0.1% Triton X 100.
- TUT buffer 6M Urea, 50mM Tris pH 8.0, 0.5% Triton X-100
- the column was eluted with 400 ⁇ l 1M NaCl, 20mM Tris pH 7.4, 0.1% Triton X 100 and fractions of 100 ⁇ l were collected and precipitated by addition of 10 ⁇ g glycogen and 3 volumes EtOH and incubated at -20°C. Precipitates were pelleted by 10 min centrifugation at 14 000 rpm, 4°C. After washing the pellets with 70% EtOH, samples were resuspended in 105 ⁇ l 100mM NaCl, 20mM Tris pH 8.0, Triton-X 100. An equal volume of 1M KOH was added for alkaline treatment and samples were incubated at 4°C for 12h. The reaction was stopped by neutralization with 7 ⁇ l of acetic acid.
- HS-chain clusters were prepared from human lung fibroblasts proteoglycans by treating the 1 st DEAE eluant (see above) with 500 ⁇ l proteinase K (2mg/ml in 20mM Tris pH 8.0) for 1h at 55 °C. The reaction was stopped by addition of 100 ⁇ l 100mM PMSF. The digest was adjusted to 200mM NaCl with TUT-buffer and concentrated on a DEAE-column (200 ⁇ l packed beads) equilibrated and washed with 200mM NaCl, 20mM Tris pH 7.4, 0.1% Triton X 100.
- the column was eluted with 400 ⁇ l 1 M NaCl, 20mM Tris pH 7.4, 0.1% Triton X 100 and fractions of 100 ⁇ l were collected and precipitated by addition of 10 ⁇ g glycogen and 3 volumes EtOH and incubated at -20°C. Precipitates were pelleted by 10 min centrifugation at 14 000 rpm, 4°C. After washing the pellets with 70% EtOH, samples were resuspended in IxABCase buffer and treated with ABCase as described above to remove CS-contaminants.
- Single HS-chains derived from alkaline treatment of HS-proteoglycans were end-labeled by aldehyde-coupling of either 2-AMAC (2-aminoacridone) or APTS (8-aminopyrene-1 ,3,6-trisulfonic acid) to the chains.
- the HS-chains were either incubated with 100mM APTS or 50mM 2-AMAC, both in formamide, by incubation with 1M NaCNBH3 at 37°C for 12h. Reaction volume 2 ⁇ l. The reaction was stopped by addition of 100 ⁇ l 20mM Tris pH 7.4.
- 2-AMAC-labeled chains were applied to DEAE- columns.
- Free 2-AMAC was eluted from the column by washing with 200mM NaCl in TUT buffer and labeled chains were eluted with 1 M NaCl. The eluant was precipitated with EtOH. APTS-labeled chains were directly purified by EtOH precipitation. The precipitates were dissolved in phosphate buffer for use in heparanase activity assays. Heparanase assay
- Cells were grown to 90% confluency in 6-well plates and transfected with 1 ⁇ g of the respective heparanase expression- or control vectors, using Fugene (Boehringer) according to the manufacturer's instructions. After 48h cells were washed and lysed in 250 ⁇ l lysis buffer (PBS ++ pH 7.2, 1% NP40, protease inhibitors) per well for 30min at 4°C. The lysate was cleared by centrifugation and 50 ⁇ l of the supernatant was incubated at the given pH-values with the respective radiolabeled HS-samples at 37°C, ON. Reactions were stopped by adding sample buffer and 5 min of boiling of the samples before they were analyzed in SDS-PAGE. HS-chains and degradation products were visualized by autoradiography or by UV-detection in the case of fluorochrome labeled chains.
- COS-1 SV40 transformed, african green monkey kidney, CRL-1650
- 293 human embryonal kidney, CRL-1573
- CaCo2 human colon adenocarcinoma, HTB-37
- CHO- K1 Choinese hamster ovary, CCL-61
- HeLa cervix carcinoma, CCL-2
- MDCK II dog kidney, CCL-34
- DMEM/F12 Gibco/Brl
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001287610A AU2001287610A1 (en) | 2000-07-12 | 2001-07-12 | A second human heparanase, and splice variants thereof, with a predominant expression in skeletal muscle, heart and pancreas |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00202442.0 | 2000-07-12 | ||
EP00202442 | 2000-07-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002004645A2 true WO2002004645A2 (en) | 2002-01-17 |
WO2002004645A3 WO2002004645A3 (en) | 2002-10-17 |
Family
ID=8171776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/008094 WO2002004645A2 (en) | 2000-07-12 | 2001-07-12 | A second human heparanase, and splice variants thereof, with a predominant expression in skeletal muscle, heart and pancreas |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001287610A1 (en) |
WO (1) | WO2002004645A2 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043830A2 (en) * | 1998-02-24 | 1999-09-02 | Pharmacia & Upjohn Company | Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity |
WO2000003036A1 (en) * | 1998-07-10 | 2000-01-20 | Insight Strategy & Marketing Ltd. | Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
WO2001000643A2 (en) * | 1999-06-25 | 2001-01-04 | Insight Strategy & Marketing Ltd. | Polynucleotides and polypeptides encoded thereby distantly homologous to heparanase |
WO2001021814A1 (en) * | 1999-09-23 | 2001-03-29 | Merck Patent Gmbh | Heparanase-2, a member of the heparanase protein family |
WO2001046392A2 (en) * | 1999-12-22 | 2001-06-28 | Oxford Glycosciences (Uk) Ltd. | Homologues of human heparanase and splice variants thereof |
WO2001048161A2 (en) * | 1999-12-23 | 2001-07-05 | Schering Aktiengesellschaft | Human heparanase-related polypeptide and nucleic acid |
WO2001077341A2 (en) * | 2000-04-11 | 2001-10-18 | Janssen Pharmaceutica N.V. | Mammalian heparanase |
WO2001079253A1 (en) * | 2000-04-18 | 2001-10-25 | Human Genome Sciences, Inc. | Extracellular matrix polynucleotides, polypeptides, and antibodies |
WO2001081569A2 (en) * | 2000-04-20 | 2001-11-01 | Pharmacia & Upjohn Company | Heparanase ii, a human heparanase paralog |
-
2001
- 2001-07-12 AU AU2001287610A patent/AU2001287610A1/en not_active Abandoned
- 2001-07-12 WO PCT/EP2001/008094 patent/WO2002004645A2/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043830A2 (en) * | 1998-02-24 | 1999-09-02 | Pharmacia & Upjohn Company | Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity |
WO2000003036A1 (en) * | 1998-07-10 | 2000-01-20 | Insight Strategy & Marketing Ltd. | Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
WO2001000643A2 (en) * | 1999-06-25 | 2001-01-04 | Insight Strategy & Marketing Ltd. | Polynucleotides and polypeptides encoded thereby distantly homologous to heparanase |
WO2001021814A1 (en) * | 1999-09-23 | 2001-03-29 | Merck Patent Gmbh | Heparanase-2, a member of the heparanase protein family |
WO2001046392A2 (en) * | 1999-12-22 | 2001-06-28 | Oxford Glycosciences (Uk) Ltd. | Homologues of human heparanase and splice variants thereof |
WO2001048161A2 (en) * | 1999-12-23 | 2001-07-05 | Schering Aktiengesellschaft | Human heparanase-related polypeptide and nucleic acid |
WO2001077341A2 (en) * | 2000-04-11 | 2001-10-18 | Janssen Pharmaceutica N.V. | Mammalian heparanase |
WO2001079253A1 (en) * | 2000-04-18 | 2001-10-25 | Human Genome Sciences, Inc. | Extracellular matrix polynucleotides, polypeptides, and antibodies |
WO2001081569A2 (en) * | 2000-04-20 | 2001-11-01 | Pharmacia & Upjohn Company | Heparanase ii, a human heparanase paralog |
Non-Patent Citations (5)
Title |
---|
DATABASE EMBL [Online] EMBL; 18 October 1999 (1999-10-18) HATTORI M ET AL.: "Homo sapiens genomic DNA, 21q region, clone: B2289H10 A012(-21)" Database accession no. AG019564 XP002155089 * |
DATABASE EMBL [Online] EMBL; 28 October 1998 (1998-10-28) STRAUSBERG R: "qg97h02.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:1843155 3', mRNA sequence" Database accession no. AI222323 XP002155088 cited in the application * |
KOSIR M A ET AL.: "Degradation of basement membrane by prostate tumor heparanase" JOURNAL OF SURGICAL RESEARCH, vol. 81, no. 1, January 1999 (1999-01), pages 42-47, XP002155606 * |
KOSIR MA ET AL.: "Human prostate carcinoma cells produce extracellular heparanase" JOURNAL OF SURGICAL RESEARCH, vol. 67, no. 1, January 1997 (1997-01), pages 98-105, XP002155605 * |
MCKENZIE E ET AL.: "Cloning and expression profiling of hpa2, a novel mammalian heparanase family member" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 276, no. 3, 5 October 2000 (2000-10-05), pages 1170-1177, XP002155087 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002004645A3 (en) | 2002-10-17 |
AU2001287610A1 (en) | 2002-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vlodavsky et al. | Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis | |
US7049407B2 (en) | Heparanase specific antibodies and their use in research and medical applications | |
EP1439193A2 (en) | Antibody directed to polypeptide having heparanase activity | |
JP2002510462A (en) | Isolated nucleic acid molecules encoding mammalian endoglucuronidase and uses thereof | |
JP2002504376A (en) | Human platelet heparanase polypeptide, polynucleotide molecule encoding the same, and method for identifying compound that modifies heparanase activity | |
US7531338B2 (en) | Purified and isolated heparan sulfate 3-O-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same | |
AU777343B2 (en) | Polynucleotides and polypeptides encoded thereby distantly homologous to heparanase | |
JP2002502611A (en) | Human heparanase polypeptide and cDNA | |
US20050282251A1 (en) | Heparanase II, a novel human heparanase paralog | |
WO2002004645A2 (en) | A second human heparanase, and splice variants thereof, with a predominant expression in skeletal muscle, heart and pancreas | |
MXPA02005077A (en) | Human heparanase-related polypeptide and nucleic acid. | |
US5637462A (en) | Cathepsin C homolog | |
CA2323833A1 (en) | Compositions and methods for the identification of lung tumor cells | |
US6677137B2 (en) | Avian and reptile derived polynucleotide encoding a polypeptide having heparanase activity | |
WO2001077341A2 (en) | Mammalian heparanase | |
JP2001228146A (en) | Use of disease-associated gene | |
WO2002033071A1 (en) | Survivin-like polypeptides and dnas thereof | |
US20050070000A1 (en) | Polynucleotides and polypeptides encoded thereby distantly homologous to heparanase | |
JP2003189878A (en) | New protein and its dna | |
JP2003219880A (en) | New protein and dna thereof | |
JP2002010791A (en) | Use for disease-related gene | |
JP2001321186A (en) | New tachykinin-like polypeptide and its use | |
WO2004000345A1 (en) | Preventives/remedies for bone and joint diseases | |
JP2002355062A (en) | Survivin-analog polypeptide and its dna | |
JP2002335964A (en) | New protein and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |